Tree Number:B01.050.150.900.649.313.750.377.750.600.500
Termes MeSH sélectionnés :
Sodium Fluoride
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Lions : Questions médicales les plus fréquentes",
"headline": "Lions : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Lions : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-04",
"dateModified": "2025-03-30",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Lions"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Panthera",
"url": "https://questionsmedicales.fr/mesh/D046009",
"about": {
"@type": "MedicalCondition",
"name": "Panthera",
"code": {
"@type": "MedicalCode",
"code": "D046009",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "B01.050.150.900.649.313.750.377.750.600"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Lions",
"alternateName": "Lions",
"code": {
"@type": "MedicalCode",
"code": "D008045",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Martin Haulena",
"url": "https://questionsmedicales.fr/author/Martin%20Haulena",
"affiliation": {
"@type": "Organization",
"name": "Vancouver Aquarium, Vancouver, BC V6G 3E2, Canada."
}
},
{
"@type": "Person",
"name": "Mads F Bertelsen",
"url": "https://questionsmedicales.fr/author/Mads%20F%20Bertelsen",
"affiliation": {
"@type": "Organization",
"name": "Centre for Zoo and Wild Animal Health, Copenhagen Zoo, Frederiksberg, Denmark."
}
},
{
"@type": "Person",
"name": "Diego Páez-Rosas",
"url": "https://questionsmedicales.fr/author/Diego%20P%C3%A1ez-Rosas",
"affiliation": {
"@type": "Organization",
"name": "Galapagos Science Center, Universidad San Francisco de Quito, Isla San Cristóbal, Islas Galápagos EC200150, Ecuador."
}
},
{
"@type": "Person",
"name": "Vincent N Naude",
"url": "https://questionsmedicales.fr/author/Vincent%20N%20Naude",
"affiliation": {
"@type": "Organization",
"name": "School of Animal, Plant & Environmental Sciences, University of the Witwatersrand, Johannesburg 2000, South Africa."
}
},
{
"@type": "Person",
"name": "Vivienne L Williams",
"url": "https://questionsmedicales.fr/author/Vivienne%20L%20Williams",
"affiliation": {
"@type": "Organization",
"name": "School of Animal, Plant & Environmental Sciences, University of the Witwatersrand, Johannesburg 2000, South Africa."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "It is strongly recommended to not conduct, fund, or publish research studies that use spot urine samples with estimating equations to assess individuals' sodium (salt) intake in association with health outcomes: a policy statement of the World Hypertension League, International Society of Hypertension and Resolve to Save Lives.",
"datePublished": "2023-01-31",
"url": "https://questionsmedicales.fr/article/36723484",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/HJH.0000000000003385"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: A retrospective nationwide claims database study in Japan.",
"datePublished": "2024-05-06",
"url": "https://questionsmedicales.fr/article/38708591",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/dom.15632"
}
},
{
"@type": "ScholarlyArticle",
"name": "The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials.",
"datePublished": "2023-05-10",
"url": "https://questionsmedicales.fr/article/37161691",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/dom.15091"
}
},
{
"@type": "ScholarlyArticle",
"name": "Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with glucagon-like peptide-1 receptor agonists (GLP-1RAs): A pooled analysis of type 2 diabetes trials.",
"datePublished": "2022-09-23",
"url": "https://questionsmedicales.fr/article/36057779",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/dom.14859"
}
},
{
"@type": "ScholarlyArticle",
"name": "The effects of sodium butyrate supplementation on the expression levels of PGC-1α, PPARα, and UCP-1 genes, serum level of GLP-1, metabolic parameters, and anthropometric indices in obese individuals on weight loss diet: a study protocol for a triple-blind, randomized, placebo-controlled clinical trial.",
"datePublished": "2023-08-01",
"url": "https://questionsmedicales.fr/article/37528450",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13063-022-06891-9"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Eucaryotes",
"item": "https://questionsmedicales.fr/mesh/D056890"
},
{
"@type": "ListItem",
"position": 3,
"name": "Animaux",
"item": "https://questionsmedicales.fr/mesh/D000818"
},
{
"@type": "ListItem",
"position": 4,
"name": "Chordés",
"item": "https://questionsmedicales.fr/mesh/D043344"
},
{
"@type": "ListItem",
"position": 5,
"name": "Vertébrés",
"item": "https://questionsmedicales.fr/mesh/D014714"
},
{
"@type": "ListItem",
"position": 6,
"name": "Mammifères",
"item": "https://questionsmedicales.fr/mesh/D008322"
},
{
"@type": "ListItem",
"position": 7,
"name": "Eutheria",
"item": "https://questionsmedicales.fr/mesh/D000073566"
},
{
"@type": "ListItem",
"position": 8,
"name": "Carnivora",
"item": "https://questionsmedicales.fr/mesh/D002335"
},
{
"@type": "ListItem",
"position": 9,
"name": "Feliformia",
"item": "https://questionsmedicales.fr/mesh/D000073568"
},
{
"@type": "ListItem",
"position": 10,
"name": "Felidae",
"item": "https://questionsmedicales.fr/mesh/D045989"
},
{
"@type": "ListItem",
"position": 11,
"name": "Panthera",
"item": "https://questionsmedicales.fr/mesh/D046009"
},
{
"@type": "ListItem",
"position": 12,
"name": "Lions",
"item": "https://questionsmedicales.fr/mesh/D008045"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Lions - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Lions",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Lions",
"description": "Comment identifier un lion dans la nature ?\nQuels tests pour évaluer la santé d'un lion ?\nQuels signes indiquent une maladie chez un lion ?\nComment diagnostiquer une infection chez un lion ?\nQuels sont les indicateurs de stress chez un lion ?",
"url": "https://questionsmedicales.fr/mesh/D008045?mesh_terms=Sodium+Fluoride&page=887#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Lions",
"description": "Quels symptômes d'une maladie courante chez les lions ?\nComment reconnaître une douleur chez un lion ?\nQuels signes indiquent une infection parasitaire ?\nQuels symptômes d'une maladie respiratoire chez un lion ?\nComment un lion montre-t-il des signes de dépression ?",
"url": "https://questionsmedicales.fr/mesh/D008045?mesh_terms=Sodium+Fluoride&page=887#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Lions",
"description": "Comment prévenir les maladies chez les lions ?\nQuelles mesures pour éviter les blessures chez les lions ?\nComment éviter le stress chez les lions en captivité ?\nQuelles pratiques alimentaires pour la santé des lions ?\nComment protéger les lions dans leur habitat naturel ?",
"url": "https://questionsmedicales.fr/mesh/D008045?mesh_terms=Sodium+Fluoride&page=887#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Lions",
"description": "Quels traitements pour une infection chez un lion ?\nComment traiter une blessure chez un lion ?\nQuels médicaments sont utilisés pour les lions ?\nComment gérer le stress chez un lion ?\nQuels soins préventifs pour les lions en captivité ?",
"url": "https://questionsmedicales.fr/mesh/D008045?mesh_terms=Sodium+Fluoride&page=887#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Lions",
"description": "Quelles complications peuvent survenir après une chirurgie chez un lion ?\nQuels risques de maladies chroniques chez les lions ?\nComment les maladies infectieuses affectent-elles les lions ?\nQuelles complications liées à l'âge chez les lions ?\nQuels effets du stress chronique sur les lions ?",
"url": "https://questionsmedicales.fr/mesh/D008045?mesh_terms=Sodium+Fluoride&page=887#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Lions",
"description": "Quels facteurs augmentent le risque de maladies chez les lions ?\nComment le braconnage affecte-t-il les lions ?\nQuels impacts de la perte d'habitat sur les lions ?\nComment le changement climatique affecte-t-il les lions ?\nQuels risques liés à la captivité pour les lions ?",
"url": "https://questionsmedicales.fr/mesh/D008045?mesh_terms=Sodium+Fluoride&page=887#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un lion dans la nature ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un lion se distingue par sa crinière, son rugissement et son comportement social en groupe."
}
},
{
"@type": "Question",
"name": "Quels tests pour évaluer la santé d'un lion ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens cliniques, des analyses sanguines et des radiographies sont utilisés."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une maladie chez un lion ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Perte d'appétit, léthargie, changements de comportement ou de pelage peuvent indiquer une maladie."
}
},
{
"@type": "Question",
"name": "Comment diagnostiquer une infection chez un lion ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests microbiologiques et des analyses de sang sont nécessaires pour diagnostiquer une infection."
}
},
{
"@type": "Question",
"name": "Quels sont les indicateurs de stress chez un lion ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un lion stressé peut montrer des comportements agités, des vocalisations excessives ou de l'agressivité."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'une maladie courante chez les lions ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent la toux, des vomissements, et des changements d'appétit."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une douleur chez un lion ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un lion peut montrer des signes de douleur par des vocalisations, une posture anormale ou une agressivité."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une infection parasitaire ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Perte de poids, diarrhée et pelage terne peuvent indiquer une infection parasitaire."
}
},
{
"@type": "Question",
"name": "Quels symptômes d'une maladie respiratoire chez un lion ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Toux, respiration rapide et écoulement nasal sont des symptômes de maladie respiratoire."
}
},
{
"@type": "Question",
"name": "Comment un lion montre-t-il des signes de dépression ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un lion déprimé peut devenir apathique, éviter les interactions sociales et perdre de l'appétit."
}
},
{
"@type": "Question",
"name": "Comment prévenir les maladies chez les lions ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des vaccinations régulières et une bonne hygiène sont essentielles pour prévenir les maladies."
}
},
{
"@type": "Question",
"name": "Quelles mesures pour éviter les blessures chez les lions ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un habitat sécurisé et des interactions contrôlées peuvent réduire le risque de blessures."
}
},
{
"@type": "Question",
"name": "Comment éviter le stress chez les lions en captivité ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Offrir un espace suffisant et des activités stimulantes aide à prévenir le stress."
}
},
{
"@type": "Question",
"name": "Quelles pratiques alimentaires pour la santé des lions ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et adaptée à leur espèce est cruciale pour leur santé."
}
},
{
"@type": "Question",
"name": "Comment protéger les lions dans leur habitat naturel ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "La conservation des habitats et la lutte contre le braconnage sont essentielles."
}
},
{
"@type": "Question",
"name": "Quels traitements pour une infection chez un lion ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les infections peuvent être traitées avec des antibiotiques et des soins de soutien."
}
},
{
"@type": "Question",
"name": "Comment traiter une blessure chez un lion ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les blessures nécessitent un nettoyage, des sutures et parfois des antibiotiques pour prévenir l'infection."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour les lions ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des analgésiques, des anti-inflammatoires et des antibiotiques sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Comment gérer le stress chez un lion ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des environnements enrichis et des interactions sociales peuvent aider à réduire le stress."
}
},
{
"@type": "Question",
"name": "Quels soins préventifs pour les lions en captivité ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des vaccinations, des examens réguliers et une alimentation équilibrée sont essentiels."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir après une chirurgie chez un lion ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent l'infection, les saignements et les réactions anesthésiques."
}
},
{
"@type": "Question",
"name": "Quels risques de maladies chroniques chez les lions ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les lions peuvent développer des maladies chroniques comme l'arthrite ou des maladies cardiaques."
}
},
{
"@type": "Question",
"name": "Comment les maladies infectieuses affectent-elles les lions ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les maladies infectieuses peuvent entraîner des épidémies et affecter la population de lions."
}
},
{
"@type": "Question",
"name": "Quelles complications liées à l'âge chez les lions ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les lions âgés peuvent souffrir de problèmes articulaires, de perte de dents et de maladies organiques."
}
},
{
"@type": "Question",
"name": "Quels effets du stress chronique sur les lions ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut entraîner des problèmes de santé mentale et physique chez les lions."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de maladies chez les lions ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge avancé, le stress et une mauvaise nutrition augmentent le risque de maladies."
}
},
{
"@type": "Question",
"name": "Comment le braconnage affecte-t-il les lions ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le braconnage réduit les populations de lions et augmente le risque d'extinction."
}
},
{
"@type": "Question",
"name": "Quels impacts de la perte d'habitat sur les lions ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "La perte d'habitat entraîne une diminution des ressources alimentaires et des conflits avec les humains."
}
},
{
"@type": "Question",
"name": "Comment le changement climatique affecte-t-il les lions ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le changement climatique modifie les écosystèmes, affectant la disponibilité de proies et d'eau."
}
},
{
"@type": "Question",
"name": "Quels risques liés à la captivité pour les lions ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les lions en captivité peuvent souffrir de stress, de maladies et de comportements anormaux."
}
}
]
}
]
}
Spot urine samples with estimating equations have been used to assess individuals' sodium (salt) intake in association with health outcomes. There is large random and systematic error in estimating so...
To date, there are limited clinical studies and real-world evidence investigating whether sodium-glucose cotransporter-2 inhibitors (SGLT2i) are associated with improved hepatic steatosis. This study ...
This retrospective cohort study included new users of SGLT2i or DPP4i with T2DM and MASLD from a large claims database (JMDC Claims Database). The primary outcome was the incidence of improvement of t...
This study included 9127 SGLT2i and 12 286 DPP4i initiators. SGLT2i showed a higher incidence of improvement in the FLI (≥30%, ≥40% and ≥50% reduction from baseline FLI) compared with DPP4i, and the w...
SGLT2is use appeared to be associated with a greater improvement of the FLI than DPP4i use in patients with T2DM and MASLD. In the absence of direct head-to-head comparisons from clinical studies, our...
To assess whether the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin affects risk of non-genital skin and soft tissue infections (SSTIs)....
We performed a post hoc pooled individual participant analysis of the CANVAS Program and CREDENCE trials that randomized people with type 2 diabetes at high cardiovascular risk and/or with chronic kid...
Overall, 903 of 14 531 participants (6%) experienced non-genital SSTIs over a median follow-up of 26 months. No difference was observed in non-genital SSTI rates between canagliflozin and placebo (24....
Canagliflozin did not affect risk of non-genital SSTIs or non-genital fungal SSTIs compared with placebo. These findings suggest that any SGLT2 inhibitor-mediated change in skin microenvironment is un...
To compare treatment effect sizes between a composite kidney outcome (CKO) and three-point major adverse cardiovascular event (MACE-3) outcomes with use of sodium-glucose cotransporter-2 (SGLT2) inhib...
We performed a MEDLINE database search up to December 31, 2021 to identify all placebo-controlled Phase 3 trials which investigated the efficacy of glucose-lowering interventions, and selected those r...
A total of 12 studies fulfilled the prespecified criteria, and comprised a total of 104 987 patients with T2D. On average, treatment effect sizes were 17% greater for CKO than for MACE-3 (rHR 0.83, 95...
In T2D patients, treatment effect sizes were greater for kidney than for macrovascular (MACE-3) outcomes, with important differences according to the drugs considered. CKO and MACE-3 are independent. ...
Obesity is a multifaceted disease characterized by an abnormal accumulation of adipose tissue. Growing evidence has proposed microbiota-derived metabolites as a potential factor in the pathophysiology...
This triple-blind randomized controlled trial (RCT) will include 50 eligible obese subjects aged between 18 and 60 years. Participants will be randomly assigned into two groups: 8 weeks of SB (600 mg/...
New evidence from this trial may help fill the knowledge gap in this realm and facilitate multi-center clinical trials with a substantially larger sample size....
Iranian Registry of Clinical Trials: IRCT20190303042905N2 . Registered on 31 January 2021....
Monotherapy to treat obesity-associated liver insult is limited....
In diet-induced obese mice showing metabolic dysfunction-associated steatotic liver disease (MASLD), we aimed to compare the combinations of sodium-glucose cotransporter-2 inhibitor (SGLT2i, empaglifl...
Male 3-month-old C57BL/6J mice were fed for 12 weeks in a control (C, n = 10) or high-fat (HF, n = 30) diet. Then, mice were followed for three additional weeks: C, HF, HF E + L, and HF E + D (n = 10/...
HF versus C showed higher hepatic triacylglycerol (TAG, +82%), steatosis (+850%), glucose intolerance (+71%), insulin (+98%), and insulin resistance (+68%). Compared to the HF group, HF E + L showed l...
PCA separated the groups considering the metabolism-related genes (glucose and lipid), mitochondrial biogenesis, and steatosis. The two pharmacological combinations showed beneficial effects in treati...
Type 2 diabetes mellitus (T2DM) is a common health issue, with heart failure (HF) being a common and lethal long-term complication. Although insulin is widely used for the treatment of T2DM, evidence ...
This study aimed to compare insulin therapy against other medications on HF risk among patients with T2DM using real-world data extracted from insurance claims....
A retrospective, observational study was conducted based on insurance claims data from a single health care network. The study period was from January 1, 2016, to August 11, 2021. The cohort was defin...
After adjusting for a broad list of confounders, patients receiving insulin were found to be associated with an 11.8% (95% CI 11.0%-12.7%), 12.0% (95% CI 11.5%-12.4%), and 15.1% (95% CI 14.3%-16.0%) h...
This study generated real-world evidence on the association of insulin therapy with a higher 5-year HF rate compared to GLP-1 RAs, DPP-4Is, and SGLT2Is based on insurance claims data. These findings a...
To compare the effectiveness of adding a glucagon-like peptide-1 receptor agonist (GLP-1 RA) with adding basal insulin among adults with type 2 diabetes (T2D) and chronic kidney disease (CKD) already ...
A retrospective analysis of the Canadian LMC Diabetes Registry was conducted. Adults who initiated a GLP-1 RA were matched 1:1 to adults who initiated basal insulin in a T2D and CKD population. Change...
Propensity score matching was used to match participants who initiated a GLP-1 RA to participants who initiated basal insulin (n = 153/cohort). A significantly greater reduction in HbA1c at 26-52 week...
The study shows the real-world effectiveness of GLP-1 RA therapy for T2D and CKD. GLP-1 RAs provided superior reductions in HbA1c and weight, and greater kidney protection, compared with basal insulin...
We assessed the effectiveness of sodium-glucose co-transporter 2 inhibitors (SGLT2is) in reducing the administration frequency of anti-vascular endothelial growth factor (VEGF) agents in patients with...
This retrospective cohort study analysed health insurance claims data covering 11 million Japanese patients between 2005 and 2019. We analysed the frequency and duration of intravitreal injection of a...
Among 2412 matched patients with DMO, the incidence rates of anti-VEGF agent injections were 230.1 per 1000 person-year in SGLT2i users and 228.4 times per 1000 person-year in non-users, respectively,...
There was no difference in the risk ratio for the addition of anti-VEGF therapy between the two treatment groups. However, the use of SGLT2is reduced the frequency of anti-VEGF agent administration in...